NEWARK, Del., Sept. 12 /PRNewswire-USNewswire/ -- Leading scientists from around the world will meet in Wilmington, Delaware next week to discuss innovative approaches for producing life-saving vaccines and antibodies. More than 125 scientists and business leaders will be participating in "New Cells for New Vaccines II: Focus on Respiratory Virus Diseases" on September 17-19 at the Hotel du Pont. The international scientific workshop is being organized by the Fraunhofer USA Center for Molecular Biotechnology (CMB) and InB:Biotechnologies, Inc. of Newark, Delaware, under the auspices of the International Association for Biologicals (IABS).
According to Dr. Vidadi Yusibov, Executive Director of the Fraunhofer USA Center for Molecular Biotechnology, "The past fifty years have seen an increase in the types of cells that can be used for vaccine and antibody production, however, there remains a need for new cell substrates that can provide safer, faster and more cost effective production alternatives to current techniques, especially with the potential threat of an influenza pandemic."
"A key aspect of the success and viability of a vaccine development project is the choice of an appropriate cell substrate," said Dr. Geoffrey Schild, Chief Scientific Officer of InB:Biotechnologies and a Director of IABS. "The advantages of plant, animal and insect cell systems are increasingly being recognized and many projects are in progress internationally, including development of respiratory virus, cervical cancer, anthrax and malaria vaccines, as well as therapeutic antibodies to treat influenza infections."
New Cells for New Vaccines II: Focus on Respiratory Virus Diseases will be of interest to scientists and business leaders in the biotechnology and pharmaceutical industry involved in vaccine development and production, as well as public health officials, medical and veterinary experts. More details and registration information are available on the meeting web site (www.NewCellsforNewVaccines.com).
About Fraunhofer USA Center for Molecular Biotechnology:
The mission of Fraunhofer USA CMB is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. CMB's technology provides a safe, rapid and economical alternative for vaccine production. Fraunhofer USA CMB is part of Fraunhofer USA, Inc., a non-profit research and development corporation, with headquarters in Michigan. It operates through technology centers that are partnered with major research universities in the United States and also with parent research institutes in Germany.
For more information, contact: Dale Ervin, Fraunhofer USA CMB at 302-369-1708 or firstname.lastname@example.org.